Iambic Therapeutics

iambic.ai →

-58%

est. 2Y upside i

HealthcareSeries C

Iambic Therapeutics tackles challenging design problems in drug discovery with its physics-based AI platform.

Rank

#3371

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

The equity is highly speculative with an expected -57.8% return over 2 years due to the extreme 59x current revenue multiple vs public comps of 5-12x.

Last updated: July 19, 2026

Bull (30%)+12%

IPO re-rating sustains 45x forward revenue multiple, yielding 12.4% net upside after dilution. Catalyst: public market appetite for AI drug discovery platforms.

Base (55%)-85%

Multiple converges to 12x (mid of public comps), revenue growth insufficient to offset compression, resulting in -84.7% net downside.

Bear (15%)-100%

Multiple falls to 6x and implied exit value of $212M below $355M total funding; common stock recovers -100% due to preference stack.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

2960%

Total funding $355M represents 29.6% of current valuation, giving preferred investors 1x liquidation preference.

Dilution Risk

high

High cash burn makes additional fundraising likely within 24 months, potentially diluting common equity by 15-25%.

Secondary Liquidity

none

No secondary market data available; equity is illiquid until an exit event.

View all 2 open roles at Iambic Therapeutics →

Last updated: July 3, 2026

Questions to Ask at the Interview

Strategic questions based on Iambic Therapeutics's data — designed to show you've done your homework.

  • 1

    “How does your physics-informed AI platform specifically de-risk clinical candidates versus competitors?”

  • 2

    “What is the revenue sustainability beyond current partnerships, and how do you plan to scale?”

  • 3

    “Given the high valuation, do you have secondary liquidity plans or an IPO timeline?”

Community

Valuation Sentiment

Our model estimates -58% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.